Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 5, 2011, Pages 338-344

  Dhote, Vipin ^a   Joharapurkar, Amit ^a   Kshirsagar, Samadhan ^a   Dhanesha, Nirav ^a   Patel, Vishal ^a   Patel, Avnish ^a   Raval, Saurin ^a   Jain, Mukul ^a  

^a ZYDUS RESEARCH CENTRE   (India)

Author keywords

Atherosclerosis; Diabetic dyslipidaemia; Microsomal triglyceride transfer proteins

Indexed keywords

CORN OIL; FATTY ACID; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TYLOXAPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; GLUCOSE TOLERANCE; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID PEROXIDATION; LIVER; MALE; NONHUMAN; RAT; RISK REDUCTION; SECRETION; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; ZUCKER RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BENZIMIDAZOLES; BLOOD GLUCOSE; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLISM; OBESITY; RATS; RATS, ZUCKER; RISK FACTORS;

EID: 79955372177     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05513.x     Document Type: Article

References (41)

1. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J. Clin. Invest. 1993; 92: 141-6.
2. Taskinen MR. Insulin resistance and lipoprotein metabolism. Curr. Opin. Lipidol. 1995; 6: 153-60.
3. Kugiyama K, Doi H, Takazoe K et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99: 2858-60.
4. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in Type 2 diabetes mellitus: Relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000; 150: 167-77.
5. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994; 106: 83-97.
6. Facchini FS, Hua NW, Reaven GM, Stoohs RA. Hyperinsulinemia. The missing link among oxidative stress and age-related diseases? Free Radic. Biol. Med. 2000; 29: 1302-6.
7. Ceriello A. Oxidative stress and glycemic regulation. Metabolism 2000; 49: 27-9.
8. Haffner SM. Clinical relevance of the oxidative stress concept. Metabolism 2000; 49: 30-4.
9. Vogel RA. Cholesterol lowering and endothelial function. Am. J. Med. 1999; 107: 479-87.
10. Sorensen KE, Kristensen IB, Celermajer DS. Atherosclerosis in the human brachial artery. J. Am. Coll. Cardiol. 1997; 29: 318-22.
11. Lewis GF, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: Studies in the fructose-fed Syrian golden hamster. Endocrinology 2005; 146: 247-55.
12. Gleeson A, Anderton K, Owens D et al. The role of microsomal triglyceride transfer protein and dietary cholesterol in chylomicron production in diabetes. Diabetologia 1999; 42: 944-8.
13. Phillips C, Bennett A, Anderton K et al. Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes. Metabolism 2002; 51: 847-52.
14. Phillips C, Owens D, Collins P, Tomkin GH. Microsomal triglyceride transfer protein: Does insulin resistance play a role in the regulation of chylomicron assembly? Atherosclerosis 2002; 160: 355-60.
15. Hagan DL, Kienzle B, Jamil H, Hariharan N. Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J. Biol. Chem. 1994; 269: 28737-44.
16. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: Insulin negatively regulates MTP gene expression. J. Lipid Res. 1995; 36: 1073-81.
17. Wetterau JR, Gregg RE, Harrity TW et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998; 282: 751-4.
18. Funatsu T, Kakuta H, Takasu T, Miyata K. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: Comparison with an MTP inhibitor. Eur. J. Pharmacol. 2002; 455: 161-7.
19. King AJ, Segreti JA, Larson KJ et al. In vivo efficacy of acyl CoA:Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia. Eur. J. Pharmacol. 2010; 637: 155-61.
20. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52: 302-10.
21. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 1974; 47: 469-74.
22. Hu X, Feng Y, Shen Y et al. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. Acta Pharmacol. Sin. 2006; 27: 1346-52.
23. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 2003; 44: 22-32.
24. Phillips MS, Liu Q, Hammond HA et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 1996; 13: 18-19.
25. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000; 148: 1-15.
26. Ockner RK, Hughes FB, Isselbacher KJ. Very low density lipoproteins in intestinal lymph: Role in triglyceride and cholesterol transport during fat absorption. J. Clin. Invest. 1969; 48: 2367-73.
27. Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J. Biol. Chem. 2002; 277: 793-803.
28. Ksander GM, deJesus R, Yuan A et al. Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J. Med. Chem. 2001; 44: 4677-87.
29. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr. Opin. Lipidol. 1998; 9: 471-4.
30. Piha M, Lindstedt L, Kovanen PT. Fusion of proteolyzed low-density lipoprotein in the fluid phase: A novel mechanism generating atherogenic lipoprotein particles. Biochemistry 1995; 34: 10120-9.
31. Ueshima K, Akihisa-Umeno H, Nagayoshi A, Takakura S, Matsuo M, Mutoh S. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: Involvement of the inhibition of postprandial triglyceride elevation. Biol. Pharm. Bull. 2005; 28: 247-52.
32. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 2008; 5: 497-505.
33. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: Progress and potential. Endocr. Rev. 1998; 19: 608-24.
34. Carpentier A, Taghibiglou C, Leung N et al. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J. Biol. Chem. 2002; 277: 28795-802.
35. Wren JA, Gossellin J, Sunderland SJ. Dirlotapide: A review of its properties and role in the management of obesity in dogs. J. Vet. Pharmacol. Ther. 2007; 30: 11-16.
36. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J. Clin. Invest. 2007; 117: 13-23.
37. Vu CB, Milne JC, Carney DP et al. Discovery of benzothiazole derivatives as efficacious and enterocyte-specific MTP inhibitors. Bioorg. Med. Chem. Lett. 2009; 19: 1416-20.
38. Bak JF, Moller N, Schmitz O, Saaek A, Pedersen O. In vivo insulin action and muscle glycogen synthase activity in Type 2 (non-insulin-dependent) diabetes mellitus: Effects of diet treatment. Diabetologia 1992; 35: 777-84.
39. Cancello R, Tounian A, Poitou C, Clement K. Adiposity signals, genetic and body weight regulation in humans. Diabetes Metab. 2004; 30: 215-27.
40. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. J. Clin. Invest. 1988; 82: 1398-406.
41. Au WS, Lu LW, Tam S et al. Pluronic L-81 ameliorates diabetic symptoms in db/db mice through transcriptional regulation of microsomal triglyceride transfer protein. World J. Gastroenterol. 2009; 15: 2987-94.